DOCK 8 Antibody (G-2): sc-376911

DOCK 8 Antibody (G-2) is a mouse monoclonal IgG1 kappa light chain antibody that detects DOCK 8 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). DOCK 8 Antibody (G-2) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. DOCK 8 protein, also known as dedicator of cytokinesis 8, is a 2,099 amino acid protein characterized by the presence of one DHR-2 (CZH-2) domain and one DHR-1 (CZH-1) domain, which are crucial for function as a guanine nucleotide exchange factor (GEF). DOCK 8 protein plays a significant role in regulating actin organization, which is essential for various cellular processes, including cell migration and division. Disruptions in DOCK 8 function can lead to severe immunological disorders, such as autosomal recessive hyper-IgE syndrome, which is marked by immunodeficiency and recurrent infections, as well as autosomal dominant mental retardation (MRD2) due to cytoskeletal abnormalities. DOCK 8 gene is located on human chromosome 9, a region that contains over 900 genes and represents nearly 4% of the human genome, highlighting importance in human health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DOCK 8 Antibody (G-2) References:

1. Isolation and characterisation of DOCK8, a member of the DOCK180-related regulators of cell morphology.  |  Ruusala, A. and Aspenström, P. 2004. FEBS Lett. 572: 159-66. PMID: 15304341
2. Dedicator of cytokinesis 8 is disrupted in two patients with mental retardation and developmental disabilities.  |  Griggs, BL., et al. 2008. Genomics. 91: 195-202. PMID: 18060736
3. Combined immunodeficiency associated with DOCK8 mutations.  |  Zhang, Q., et al. 2009. N Engl J Med. 361: 2046-55. PMID: 19776401
4. DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation.  |  Jabara, HH., et al. 2012. Nat Immunol. 13: 612-20. PMID: 22581261
5. Clinical, immunological and molecular characterization of DOCK8 and DOCK8-like deficient patients: single center experience of twenty-five patients.  |  Alsum, Z., et al. 2013. J Clin Immunol. 33: 55-67. PMID: 22968740
6. Defective actin accumulation impairs human natural killer cell function in patients with dedicator of cytokinesis 8 deficiency.  |  Mizesko, MC., et al. 2013. J Allergy Clin Immunol. 131: 840-8. PMID: 23380217
7. Novel dedicator of cytokinesis 8 mutations identified by multiplex ligation-dependent probe amplification.  |  Tóth, B., et al. 2013. Eur J Haematol. 91: 369-75. PMID: 23859592
8. Aberrant humoral immune reactivity in DOCK8 deficiency with follicular hyperplasia and nodal plasmacytosis.  |  aan de Kerk, DJ., et al. 2013. Clin Immunol. 149: 25-31. PMID: 23891736
9. Wiskott-Aldrich Syndrome (WAS) and Dedicator of Cytokinesis 8- (DOCK8) Deficiency.  |  Albert, MH. and Freeman, AF. 2019. Front Pediatr. 7: 451. PMID: 31750279
10. Atypical Localization of Eczema Discriminates DOCK8 or STAT3 Deficiencies from Atopic Dermatitis.  |  Kasap, N., et al. 2023. J Clin Immunol. 43: 1882-1890. PMID: 37507632
11. Metabolic fitness of IgA+ plasma cells in the gut requires DOCK8.  |  Zhang, B., et al. 2024. Mucosal Immunol. 17: 431-449. PMID: 38159726
12. Dedicator of cytokinesis 8 (DOCK8) mutation impairs the differentiation of helper T cells by regulating the glycolytic pathway of CD4+ T cells.  |  Jiang, P., et al. 2024. MedComm (2020). 5: e747. PMID: 39329018

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-DOCK 8 Antibody (G-2) has 4 citations in a variety of scientific publications.

Primary antibodies like Anti-DOCK 8 Antibody (G-2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

DOCK 8 Antibody (G-2) Specifications

Alternate Product Name: DOCK 8

Product Clone Name: G-2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 119-277

Epitope Target: DOCK 8

Epitope Species: human

Product Reactivity/Detection: DOCK 8

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 4 citations in various scientific publications

Available Conjugates/Forms for DOCK 8 Antibody (G-2): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin